The Swiss pharmaceutical giant Novartis announced on Monday positive results of its phase 2 clinical trials of an antiviral treatment against COVID-19 developed with the Swiss laboratory Molecular Partners.
LOOK | The European country that already plans to treat the coronavirus like a common flu: what is the strategy like
Called ensovibep, this intravenously administered treatment achieved its primary goals in phase 2 trials, which corresponds to the intermediate phase of clinical studies, of reducing viral load after eight days for the three doses tested, he says. Novartis it’s a statement.
It also reached its secondary objectives related to hospitalizations and / or admissions to intensive care or deaths, achieving a risk reduction of 78% for patients who received this treatment, compared to those who received a placebo, the Swiss group points out.
This phase 2 study, called Empathy, was carried out with 407 adult outpatients.
In vitro tests showed a high level of neutralization against all known variants, including delta and omicron, the group adds.
Novartis joined the Zurich biotechnology laboratory, Molecular Partners, in October 2020, signing an agreement on the development of two potential antiviral treatments against COVID-19, among them the MP0420, later called ensovibep.
According to the criteria of